REGENEREX PHARMA, INC.: 10-Q filed 2020-02-10
What REGENEREX PHARMA, INC. reported in its quarterly report filed 2020-02-10 (fiscal Q3 2019): 28 published measures, 68 facts as tagged in accession 0001472375-20-000007.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2020-02-10
- Fiscal period
- fiscal Q3 2019
- Accession
- 0001472375-20-000007 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGENEREX PHARMA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 254,747 | USD | |
| At 2019-03-31 | 105,623 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 695,725 | USD | |
| At 2019-03-31 | 475,308 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | -440,978 | USD | |
| At 2019-03-31 | -369,685 | USD | |
| At 2018-12-31 | -353,233 | USD | |
| At 2018-03-31 | -321,106 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 3,137 | USD | |
| At 2019-03-31 | 88,546 | USD | |
| At 2018-12-31 | 32,079 | USD | |
| At 2018-03-31 | 1,728 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | -20,554 | USD | 92 |
| 2019-04-01 to 2019-12-31 | -71,293 | USD | 275 |
| 2018-10-01 to 2018-12-31 | -53,745 | USD | 92 |
| 2018-04-01 to 2018-12-31 | -77,127 | USD | 275 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-12-31 | 220,960 | USD | 275 |
| 2018-04-01 to 2018-12-31 | 23,523 | USD | 275 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | 1,671 | USD | 92 |
| 2019-04-01 to 2019-12-31 | 1,671 | USD | 275 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-12-31 | 135,551 | USD | 275 |
| 2018-04-01 to 2018-12-31 | 53,874 | USD | 275 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | -1,345,054 | USD | |
| At 2019-03-31 | -1,273,761 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-04-01 to 2018-12-31 | 45,000 | USD | 275 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | -12,628 | USD | 92 |
| 2019-04-01 to 2019-12-31 | -55,371 | USD | 275 |
| 2018-10-01 to 2018-12-31 | -52,290 | USD | 92 |
| 2018-04-01 to 2018-12-31 | -75,679 | USD | 275 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 250,758 | USD | |
| At 2019-03-31 | 97,616 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | -8,028 | USD | 92 |
| 2019-04-01 to 2019-12-31 | -17,917 | USD | 275 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 490,176 | USD | |
| At 2019-03-31 | 405,308 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 115,297 | USD | |
| At 2019-03-31 | 38,348 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 3,989 | USD | |
| At 2019-03-31 | 8,007 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | 14,105 | USD | 92 |
| 2019-04-01 to 2019-12-31 | 56,848 | USD | 275 |
| 2018-10-01 to 2018-12-31 | 52,290 | USD | 92 |
| 2018-04-01 to 2018-12-31 | 75,679 | USD | 275 |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | 1,477 | USD | 92 |
| 2019-04-01 to 2019-12-31 | 1,477 | USD | 275 |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | 194 | USD | 92 |
| 2019-04-01 to 2019-12-31 | 194 | USD | 275 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2018-12-31 | 300 | USD | 92 |
| 2018-04-01 to 2018-12-31 | 300 | USD | 275 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 127,112,660 | shares | |
| At 2019-03-31 | 127,112,660 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 776,963 | USD | |
| At 2019-03-31 | 776,963 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 22,695 | USD | |
| At 2019-03-31 | 14,778 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-12-31 | 71,293 | USD | 275 |
| 2018-04-01 to 2018-12-31 | -45,000 | USD | 275 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | 12,535 | USD | 92 |
| 2019-04-01 to 2019-12-31 | 40,745 | USD | 275 |
| 2018-10-01 to 2018-12-31 | 51,990 | USD | 92 |
| 2018-04-01 to 2018-12-31 | 75,379 | USD | 275 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-12-31 | 4,018 | USD | 275 |
| 2018-04-01 to 2018-12-31 | 4,019 | USD | 275 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-12-31 | 1,344 | USD | 275 |
| 2019-04-01 to 2019-06-30 | 1,344 | USD | 91 |
| 2018-04-01 to 2018-12-31 | 4,019 | USD | 275 |
| 2018-04-01 to 2018-06-30 | 4,018 | USD | 91 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-12-31 | -124,226 | USD | 275 |
Inspect the source
- Entity
- REGENEREX PHARMA, INC. / CIK 0001357878
- Captured
- 2026-09-21T17:18:44.819Z
- SEC response SHA-256
213194c506fa9441e1992f90b01cc25fc346a1dd3e1f77e4d19752e41180a033
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001357878.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))